XML 71 R54.htm IDEA: XBRL DOCUMENT

Quarterly Results of Operations (unaudited) (Tables)

12 Months Ended

Dec. 31, 2023

Quarterly Financial Data [Abstract]

Unaudited consolidated quarterly results of operations

The unaudited consolidated quarterly results of operations (in thousands, except per share data) were as follows:


			For the Three Months Ended
			December 31						September 30						June 30						March 31
2023
Total revenue			$	556,055					$	511,015					$	469,136					$	427,690
Total operating expenses			577,405						528,953						490,704						438,045
Loss before preferred dividends and accretion of Series A Preferred Stock			(33,411)						(25,324)						(34,323)						(19,982)
Dividends and accretion of Series A Preferred Stock			(7,984)						(7,872)						(7,088)						(6,276)
Net loss attributable to common shareholders of Evolent Health, Inc.			(41,395)						(33,196)						(41,411)						(26,258)

Loss per common share


			For the Three Months Ended
			December 31						September 30						June 30						March 31
Basic and diluted			$	(0.36)					$	(0.30)					$	(0.37)					$	(0.24)


2022
Total revenue			$	382,432					$	352,585					$	319,939					$	297,057
Total operating expenses			384,310						339,634						324,572						299,855
Net income (loss) from continuing operations			(11,349)						2,123						(4,125)						(5,350)
Net loss from discontinued operations, net of tax			—						—						(463)						—
Net income (loss) attributable to common shareholders of Evolent Health, Inc.			(11,349)						2,123						(4,588)						(5,350)

Income (loss) per common share
Basic and diluted			$	(0.11)					$	0.02					$	(0.05)					$	(0.06)